F. HOFFMANN-LA ROCHE AG;VIB VZW;LIFE SCIENCES RESEARCH PARTNERS VZW
发明人:
申请号：
ARP120103189
公开号：
AR087714A1
申请日:
2012.08.29
申请国别(地区):
AR
年份:
2014
代理人:
摘要：
This is a method to predict the possibility of developing hypertension in anti angioplasty therapy (such as bevazumab) by determining the gene type of KDR gene and / or EGF gene. This document also mentions a pharmaceutical ingredient, including angioplasty inhibitors such as bevazumab, for the treatment of a cancer patient based on the gene type of KDR and / or EGF genes. This paper also discusses a way to reduce the risk of hypertension in cancer patients, such as bevazumab,KDR and / or EGF genes were identified by genotyping. 1. Claim 1: a method for determining the sensitivity of patients to the development of hypertension, which is associated with the treatment of VEGF entry basically the same as bevazumab, including angioplasty inhibitors or antibodies, including bevazumab, including: (a) determining in samples Genotype variant rs23005949 from a cancer patient (Section 3)E (b) according to the genotype, determine the extent to which a patient is susceptible to the development of hypertension related to the treatment of angioplasty inhibitors, including bevazumab, or antibodies related to VEGF entries that are essentially the same as bevazumab, Genotype CC in polymorphic rs23005949 (Section 3) indicated that the patient was more likely to develop hypertension than those who showed genotype traditional knowledge or TT in rs23005949 (Section 3).The presence of genotype TT or gene technology in polymorphic rs23005949 (Section 3) suggests that the patient is less likely to develop hypertension than the patient with genotype CC in polymorphic rs23005949 (Section 3).La presente se refiere a un método de predicción de la susceptibilidad de un paciente a desarrollar hipertensión asociada a un tratamiento antiangiogénesis, tal como bevacizumab, mediante la determinación del genotipo del gen KDR y/o del gen EGF. La presente se refiere además a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un pacie
